I’m going to need you to read this twice because it sounds like science fiction. SonoNeu just emerged from stealth with a platform that uses ultrasound to control engineered cells inside the body. No small molecules. No biologics. No drugs at all, actually. Just sound waves and synthetic biology doing things together that neither can do alone.
The concept is called sonogenetics — pioneered by SonoNeu founder Sreekanth Chalasani — and it works by engineering cells to express ultrasound-responsive proteins, then using focused ultrasound to activate them noninvasively. Think of it as a remote control for cellular function. The initial targets? Peripheral neuropathy and diabetic neuropathy, conditions where precise neuromodulation could be transformative.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
And the backing here isn’t from a VC — it’s from ARPA-H, the government’s moonshot health agency. The total program is worth up to $41.3 million, led by the Salk Institute with a multi-institutional academic consortium. SonoNeu is the commercial lead, pulling up to $5.2 million to handle the development-to-clinic translation.
This is the second ARPA-H stealth launch today (more on that below), and it tells you something about where government funding is headed — away from incremental improvements and toward platform technologies that rewrite the rules entirely. Sonogenetics isn’t competing with existing drug classes. It’s creating a new one.
The Palo Alto-based company sits at the intersection of neuromodulation and synthetic biology, two fields that have been circling each other for years. SonoNeu is the bet that they finally collide. Early days — preclinical, no named assets yet — but the mechanism is genuinely novel, and ARPA-H doesn’t write $41M checks for incremental science.
